Common Contracts

NOTE PURCHASE AGREEMENT dated February 21, 2020 among THERAVANCE BIOPHARMA R&D, INC., TRIPLE ROYALTY SUB II LLC and THE PURCHASER NAMED HEREIN $400,000,000 TRIPLE II 9.5% FIXED RATE TERM NOTES DUE 2035

Note Purchase Agreement • February 27th, 2020 • Theravance Biopharma, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Note Purchase Agreement
• Filed
  February 27th, 2020
• Company
  Theravance Biopharma, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Triple Royalty Sub II LLC, a Delaware limited liability company (the “Issuer”), and Theravance Biopharma R&D, Inc., a Cayman Islands exempted company (“Theravance Biopharma R&D”), hereby covenant and agree with you as follows:

NOTE PURCHASE AGREEMENT dated November 30, 2018 among THERAVANCE BIOPHARMA R&D, INC., TRIPLE ROYALTY SUB LLC and THE PURCHASER NAMED HEREIN

Note Purchase Agreement • December 3rd, 2018 • Theravance Biopharma, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Note Purchase Agreement
• Filed
  December 3rd, 2018
• Company
  Theravance Biopharma, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Triple Royalty Sub LLC, a Delaware limited liability company (the “Issuer”), and Theravance Biopharma R&D, Inc., a Cayman Islands exempted company (“Theravance Biopharma R&D”), hereby covenant and agree with you as follows: